A private public partnership to strengthen Australia’s position at the forefront of the cancer treatment revolution.
The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia is a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives.
Announced by the Australian Government at the Garvan Institute of Medical Research today.
Over the past decade, immunotherapy and other new treatments have transformed outcomes for thousands of Australians diagnosed with cancer. However, 46,000 Australians a year are diagnosed with cancers with limited treatment options.
[Read more…] about $185 million investment to fast-track treatments for rare and ‘untreatable’ cancers